<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01790022</url>
  </required_header>
  <id_info>
    <org_study_id>METALL 2012</org_study_id>
    <nct_id>NCT01790022</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of MEthylprednisolone Administered Intravenously for the Treatment of Patients With Active AnkyLosing spondyLitis (METALL)</brief_title>
  <acronym>METALL</acronym>
  <official_title>Efficacy and Safety of MEthylprednisolone Administered Intravenously for the Treatment of Patients With Active AnkyLosing spondyLitis (METALL) - a 12-week, Prospective, Open-label, Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Saratov State Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Saratov State Medical University</source>
  <brief_summary>
    <textblock>
      In this study, efficacy of methylprednisolone in reduction of signs and symptoms (back pain,&#xD;
      stiffness, joint pain and swelling) of active ankylosing spondylitis (AS) will be&#xD;
      investigated. It is expected, that a single dose of methylprednisolone 500 mg given&#xD;
      intravenously at baseline will lead to a rapid reduction of symptoms of active AS, which can&#xD;
      be seen already 2 weeks after drug administration.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>July 2012</start_date>
  <primary_completion_date type="Anticipated">March 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Assessment of Spondyloarthritis International Society 40 (ASAS40) response</measure>
    <time_frame>Week 2</time_frame>
    <description>The Assessment of Spondyloarthritis International Society 40 (ASAS40) response is defined as an improvement of ≥40% and ≥2 points in at least 3 out of four following domains (and no worsening in remaining domain):&#xD;
Patient global&#xD;
Pain&#xD;
Function (as measured by the Bath Ankylosing Spondylitis Functional Index - BASFI)&#xD;
Inflammation (mean of the Bath Ankylosing Spondylitis Disease Activity Index - BASDAI question 5 and 6)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Ankylosing Spondylitis</condition>
  <arm_group>
    <arm_group_label>Methylprednisolone 500 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Methylprednisolone 500 mg administered intravenously at baseline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone</intervention_name>
    <arm_group_label>Methylprednisolone 500 mg</arm_group_label>
    <other_name>Metypred, Medrol, Solu-Medrol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age of ≥18 years.&#xD;
&#xD;
          -  Definite diagnosis of AS according to the modified New York criteria.&#xD;
&#xD;
          -  History of an inadequate response to ≥2 nonsteroidal antiinflammatory drugs (NSAIDs)&#xD;
             taken for at least 2 weeks each or NSAIDs intolerance.&#xD;
&#xD;
          -  Active disease as defined by the Bath Ankylosing Spondylitis DIsease Activity Index&#xD;
             (BASDAI) value of ≥4 at screening despite concomitant treatment with an NSAID or&#xD;
             without NSAIDs in case of intolerance.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The female subject is pregnant or lactating.&#xD;
&#xD;
          -  Patients with other chronic inflammatory articular disease or systemic autoimmune&#xD;
             disease.&#xD;
&#xD;
          -  History of inadequate response to previous anti-tumour necrosis factor (TNF) α&#xD;
             therapy.&#xD;
&#xD;
          -  Treatment with any other investigational drug within 4 weeks of 5 half-life of the&#xD;
             drug (whichever is longer) prior to baseline.&#xD;
&#xD;
          -  Treatments with disease modifying anti-rheumatic drugs (DMARDs) other than&#xD;
             methotrexate within 4 weeks prior to screening (8 weeks for leflunomide or 4 weeks&#xD;
             with a standard cholestyramine wash-out).&#xD;
&#xD;
          -  Treatment with intravenous, intramuscular or intraarticular/periarticular steroids&#xD;
             within 4 weeks prior to screening.&#xD;
&#xD;
          -  History of oesophageal, gastric, duodenal or intestinal ulceration, clinically&#xD;
             relevant gastrointestinal bleeding.&#xD;
&#xD;
          -  History of or current signs of coronary heart disease, myocardial infarction, stroke&#xD;
             or transient ischemic attack, peripheral arterial thrombotic events.&#xD;
&#xD;
          -  Congestive heart failure (NYHA III-IV)&#xD;
&#xD;
          -  Uncontrolled arterial hypertension.&#xD;
&#xD;
          -  History of diabetes mellitus.&#xD;
&#xD;
          -  History of glaucoma.&#xD;
&#xD;
          -  Major surgery within 12 weeks prior to screening.&#xD;
&#xD;
          -  Evidence of any other severe uncontrolled gastrointestinal, hepatic, renal, pulmonary,&#xD;
             cardiovascular, nervous or endocrine disorders.&#xD;
&#xD;
          -  Any active current viral, bacterial or fungal infection, a history of recurrent&#xD;
             clinically significant infection, infections requiring treatment with antibiotics&#xD;
             within 4 weeks prior to baseline.&#xD;
&#xD;
          -  History of chronic infection with hepatitis B or C, history of HIV infection.&#xD;
&#xD;
          -  Primary or secondary immunodeficiency.&#xD;
&#xD;
          -  Any other conditions making the patient unsuitable in the opinion of the investigator&#xD;
             for the participation in the current study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Rheumatology, Saratov Region Hospital</name>
      <address>
        <city>Saratov</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <study_first_submitted>February 9, 2013</study_first_submitted>
  <study_first_submitted_qc>February 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2013</study_first_posted>
  <last_update_submitted>February 9, 2013</last_update_submitted>
  <last_update_submitted_qc>February 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 12, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Saratov State Medical University</investigator_affiliation>
    <investigator_full_name>Denis Poddubnyy</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spondylitis</mesh_term>
    <mesh_term>Spondylitis, Ankylosing</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Acetate</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

